header-logo
GettyImages-609179959-hero
Pathology & Laboratory Medicine
Navonil De Sarkar, PhD

Navonil De Sarkar, PhD

Assistant Professor

Locations

  • TBRC, 4th Floor

Contact Information

Education

PhD, University of Calcutta, Indian Statistical Institute, India

Biography

I am a researcher with over 15 years of experience in precision medicine, focusing on identifying genomic and epigenomic modifications in prostate cancer that contribute to metastasis and therapy resistance. My work involves developing novel algorithms and performing genomics and functional analysis to identify clinically relevant markers for diagnostics and precision therapy development. I have contributed to several landmark and practice-changing research studies (NEJM 2016, Nature Medicine 2016, PNAS 2019, Nature Communication 2021, Cancer Discovery 2023). As the leader of my research group, I envision collaborating closely with clinicians and translational scientists to pursue a multidisciplinary approach to my research, resulting in productive research publications and clinical trials.

During my training, I became an expert in large-scale cancer genome and epigenome analysis, both in wet lab assays and bioinformatics. My training includes graduate studies at the Indian Statistical Institute and a postdoctoral fellowship with Dr. Peter S. Nelson, a leader in prostate cancer genomics. My expertise includes analyzing tumor genomes, studying functionally relevant mutations, and developing machine learning frameworks for predicting homologous recombination deficiency.

Honors and Awards

PCF Young Investigator Award, 2019

Research Areas of Interest

  • Aged
  • Animals
  • Base Pair Mismatch
  • Biomarkers, Tumor
  • Carboplatin
  • Cell Line, Tumor
  • Circulating Tumor DNA
  • DNA Repair
  • Fanconi Anemia Complementation Group D2 Protein
  • Fanconi Anemia Complementation Group N Protein
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic

Research Experience

  • Adenocarcinoma
  • Aged
  • Aged, 80 and over
  • Androgens
  • Animals
  • Ataxia Telangiectasia Mutated Proteins
  • Biomarkers, Tumor
  • Cell Line, Tumor
  • Cell Proliferation
  • Circulating Tumor DNA
  • DNA Repair
  • Down-Regulation

Clinical Expertise

  • Humans

Methodologies and Techniques

  • Aged
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Middle Aged
  • Prostatic Neoplasms

Research Interests

A significant focus of my research is the study of circulating tumor DNA (ctDNA) from liquid biopsies in patients with metastatic prostate cancer. My work in this area has led to the development of novel computational tools and a targeted sequencing panel optimized for ctDNA assays. In a 2023 study published in Cancer Discovery, we demonstrated that nucleosome patterns in ctDNA can reveal transcriptional regulation of advanced prostate cancer phenotypes. By sequencing plasma ctDNA whole genomes from patient-derived xenografts, we identified nucleosome positioning patterns associated with transcriptional activity at regions of genes, promoters, histone modifications, transcription factor binding, and accessible chromatin. This study highlighted the activity of key phenotype-defining transcriptional regulators, such as AR, ASCL1, HOXB13, HNF4G, and GATA2. To distinguish neuroendocrine prostate cancer (NEPC) and androgen receptor active prostate cancer (ARPC) in patient plasma samples, we developed prediction models that achieved accuracies of 97% for dominant phenotypes and 87% for mixed clinical phenotypes. This approach provides diagnostic advantages for precision oncology, demonstrating that ctDNA can offer comparable results to traditional methods like immunohistochemistry or transcriptome profiling from tumor biopsies.

My other interest areas include developing therapeutic strategies to overcome treatment resistance in advanced prostate cancers, particularly through novel approaches to DNA-damaging agents. I am dedicated to developing biomarkers for DNA-damaging agent sensitivity and expanding the scope of various DNA-damaging therapies, such as radiation, PARP inhibitors, and radionuclide therapies. Additionally, I am pioneering methods to assess tumor genomic and epigenomic aberrations using circulating tumor DNA.

Publications

Publications of Navonil De Sarkar PhD from the Faculty Collaboration Database

© 2025 Medical College of Wisconsin.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination Statement
The Medical College of Wisconsin (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.

Notice of Compliance with Laws and Commitment to Civil Rights
The Medical College of Wisconsin is committed to full compliance with all applicable federal, state, and local laws and regulations in the pursuit of our mission. Consistent with recent federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making. As part of this commitment, we are actively reviewing our policies and materials to ensure they align with federal nondiscrimination obligations.